Development and clinical validation of blood-based multibiomarker models for the evaluation of brain amyloid pathology.

ABSTRACT:

Background and objectives

Plasma biomarkers provide new tools to evaluate patients with mild cognitive impairment (MCI) for Alzheimer's disease (AD) pathology. Such tools are needed for anti-amyloid therapies that require efficient and accurate diagnostic evaluation to identify potential treatment candidates. This study sought to develop and evaluate the clinical performance of a multi-marker combination of plasma beta-amyloid 42/40 (Aβ42/40), ptau-217, and APOE genotype to predict amyloid PET positivity in a diverse cohort of patients at a memory clinic and evaluate >4,000 results from "real-world" specimens submitted for high-throughput clinical testing.

Methods

Study participants were from the 1Florida AD Research Center (ADRC). Demographics, clinical evaluations,

SUBMITTER: Weber DM 

PROVIDER: S-EPMC12045422 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature